Trivedi Vinod, Von Lindern Jana, Montes-Walters Miguel, Rojo Daniel R, Shell Elisabeth J, Parkin Neil, O'Brien William A, Ferguson Monique R
Department of Internal Medicine, Division of Infectious Diseases, The University of Texas Medical Branch, Galveston, Texas 77555-0435, USA.
AIDS Res Hum Retroviruses. 2008 Oct;24(10):1291-300. doi: 10.1089/aid.2007.0244.
The role specific reverse transcriptase (RT) drug resistance mutations play in influencing phenotypic susceptibility to RT inhibitors in virus strains with complex resistance interaction patterns was assessed using recombinant viruses that consisted of RT-PCR-amplified pol fragments derived from plasma HIV-1 RNA from two treatment-experienced patients. Specific modifications of key RT amino acids were performed by site-directed mutagenesis. A panel of viruses with defined genotypic resistance mutations was assessed for phenotypic drug resistance. Introduction of M184V into several different clones expressing various RT resistance mutations uniformly decreased susceptibility to abacavir, lamivudine, and didanosine, and increased susceptibility to zidovudine, stavudine, and tenofovir; replication capacity was decreased. The L74V mutation had similar but slightly different effects, contributing to decreased susceptibility to abacavir, lamivudine, and didanosine and increased susceptibility to zidovudine and tenofovir, but in contrast to M184V, L74V contributed to decreased susceptibility to stavudine. In virus strains with the nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations K101E and G190S, the L74V mutation increased replication capacity, consistent with published observations, but replication capacity was decreased in strains without NNRTI resistance mutations. K101E and G190S together tend to decrease susceptibility to all nucleoside RT inhibitors, but the K103N mutation had little effect on nucleoside RT inhibitor susceptibility. Mutational interactions can have a substantial impact on drug resistance phenotype and replication capacity, and this has been exploited in clinical practice with the development of fixed-dose combination pills. However, we are the first to report these mutational interactions using molecularly cloned recombinant strains derived from viruses that occur naturally in HIV-infected individuals.
利用重组病毒评估了特定逆转录酶(RT)耐药性突变在具有复杂耐药性相互作用模式的病毒株中对RT抑制剂表型敏感性的影响,这些重组病毒由来自两名接受过治疗的患者血浆HIV-1 RNA的RT-PCR扩增的pol片段组成。通过定点诱变对关键RT氨基酸进行特定修饰。对一组具有明确基因型耐药性突变的病毒进行了表型耐药性评估。将M184V引入几个表达各种RT耐药性突变的不同克隆中,均降低了对阿巴卡韦、拉米夫定和去羟肌苷的敏感性,并增加了对齐多夫定、司他夫定和替诺福韦的敏感性;复制能力下降。L74V突变具有相似但略有不同的影响,导致对阿巴卡韦、拉米夫定和去羟肌苷的敏感性降低,对齐多夫定和替诺福韦的敏感性增加,但与M184V不同的是,L74V导致对司他夫定的敏感性降低。在具有非核苷逆转录酶抑制剂(NNRTI)突变K101E和G190S的病毒株中,L74V突变增加了复制能力,这与已发表的观察结果一致,但在没有NNRTI耐药性突变的病毒株中复制能力下降。K101E和G190S共同倾向于降低对所有核苷RT抑制剂的敏感性,但K103N突变对核苷RT抑制剂敏感性影响不大。突变相互作用可对耐药性表型和复制能力产生重大影响,这一点已在临床实践中通过开发固定剂量复方药丸得到应用。然而,我们是第一个使用源自HIV感染个体自然存在的病毒的分子克隆重组株报告这些突变相互作用的。